



Quotes & Research Market Activity News Investing Personal Finance My Nasdaq Register | Log In

## RBCC and Therakine Initiate Phase II of Drug Delivery Development

By Business Wire, December 12, 2013, 05:00:00 AM EDT

Vote up



MIRAMAR BEACH, Fla.--(BUSINESS WIRE)-- Rainbow Coral Corp. (OTCBB:RBCC) and its joint venture partner, Therakine, Ltd., are pleased to announce that they have reached a major new milestone in the development of a revolutionary new drug delivery technology. This week, the companies reached terms to initiate Phase II of research and analysis on a new injectable, sustained-release technology poised to vastly improve patients' use of a crucial drug in the fight against drug and alcohol dependence.



### You'll Love Our Free RBCC Analysis

My name is Tracey Ryniec and I'm giving you a detailed report on RBCC from Zacks Investment Research.

It predicts where that stock will head in 1 to 3 months. The report applies our earnings-based system that nearly tripled the market since 1988.

But RBCC might not be your best choice. So you will also receive a second report, *5 Stocks to Double* with my compliments.

[Get free RBCC analysis and 5 Stocks to Double](#)

Naltrexone is a prescription opioid receptor antagonist used primarily in the management of alcohol and opioid dependence. Phase I of the joint venture's research established excellent compatibility between the drug and Therakine's hydrophobic injection matrix as well as a highly promising release profile. Phase II will focus on micronization of the technology as well as extension of its sustained release time.

RBCC has big plans for the breakthrough technology in 2014. If Phase II of research goes as well as Phase I did, the joint venture could soon supply the only intramuscular, programmable release of Naltrexone available anywhere in the \$142.5 billion drug delivery industry.

"We believe this sustained-release tech is going to forever change the way addiction is treated around the globe," said new RBCC CEO Kimberly Palmer. "We're already in talks with Therakine about potentially acquiring an exclusive, international distribution license for this product. We're expecting next year to be tremendously fruitful for our company and our investors."

RBCC's biotech division, Rainbow BioSciences, is working with partners such as Therakine to capitalize on the incredible growth of the global drug delivery market by delivering new medical and research technology innovations in order to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: [BMY](#)), Biogen Idec Inc. (NASDAQ: [BIIB](#)), Abbott Laboratories (NYSE: [ABT](#)) and Valeant Pharmaceuticals International (NYSE: [VRX](#)).

See headlines for [ABT](#)

[View](#) [Print Version](#)

More from Business Wire

- ▶ [RBCC Moves to the Front Lines of the 3D Bioprinting Revolution](#)
- ▶ [RBCC Prepares Big Push Into Booming 3D Bioprinting Market](#)
- ▶ [RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase](#)

#### Referenced Stocks

[ABT](#) 80% [Rate It](#)

[BIIB](#) 86% [Rate It](#)

[BMY](#) 75% [Rate It](#)

[VRX](#) 100% [Rate It](#)

Most Popular **Highest Rated**

- ▶ [Asian Markets Trading Weak Ahead Of Key China Data Release](#)
- ▶ [AB Inbev Nearing \\$4.5 Billion Deal to Reacquire Oriental Brewery --](#)
- ▶ [Gilead: European Commission Grants Marketing Authorization For Sovaldi](#)
- ▶ [Plextronics Files for Bankruptcy. Has \\$32.6 Million Buyout Offer](#)
- ▶ [Japan Economy 'Recovering for 1st Time Since 2008](#)

Dell's 2020 Legacy of Good plan.

See how Dell is bringing sustainability and business together.

[Learn More >](#)

For more information on RBCC's other biotech initiatives, please visit [www.rainbowbiosciences.com](http://www.rainbowbiosciences.com).

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit [www.RainbowBioSciences.com](http://www.RainbowBioSciences.com).

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Source: Rainbow Coral Corp.

This article appears in: [News Headlines](#)

Referenced Stocks: [ABT](#), [BIIB](#), [BMY](#), [RBCC](#), [VRX](#)

- [Pre-owned Vehicles](#)
- [Free Cell Phone Plan](#)
- [Easy Appetizer Recipes](#)
- [Best Cell Phone](#)
- [Gmail Account](#)
- [High Speed Internet](#)

Related Topics

Latest News Video



[1,500 Military Jobs to Be Lost](#)




Related stocks Articles

- [LSI Beats on Q4 Earnings Estimates - Analyst Blog](#)  
 1/23/2014 10:40 AM
- [Q4 Shaping Up to be No Different - Ahead of Wall Street](#)  
 1/23/2014 10:35 AM
- [SanDisk Beats Q4 Earnings Estimates - Analyst Blog](#)  
 1/23/2014 10:30 AM



[Pentagon May Save BlackBerry from E...](#)



Most Active by Volume		
Company	Last Sale	Change Net / %
<a href="#">BAC</a>	\$ 16.90	0.25 ▼ 1.46%
<a href="#">NOK</a>	\$ 6.99	0.71 ▼ 9.22%
<a href="#">EBAY</a>	\$ 55.06	0.65 ▲ 1.19%
<a href="#">GE</a>	\$ 25.82	0.17 ▼ 0.65%
<a href="#">FB</a>	\$ 56.14	1.37 ▼ 2.38%
<a href="#">ARIA</a>	\$ 7.279	0.57 ▲ 8.48%
<a href="#">SC</a>	\$ 26	unch
<a href="#">AA</a>	\$ 12.05	0.17 ▼ 1.39%

[View more in Most Active](#)

[NYC Mayor on UPE](#)  
[Snowplow Efforts:...](#)



[About NASDAQ OMX](#) [NASDAQ OMX Technology](#) [NASDAQ OMX Listing Center](#) [Investor Relations](#)

[Public Policy Advocacy](#) [Join Our Community](#) [Sitemap](#) [Advertise With Us](#) [Feedback](#) [Terms of Use](#)

[Privacy Statements](#) [Contact](#) [Annual Reports](#)

